Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Active Not Recruiting Phase 2 Trials for Gemcitabine (DB00441)

Also known as: Resectable Pancreatic Ductal Adenocarcinoma

Indication	Status	Phase
DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC))	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04481204	New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study	Treatment	Albumin human (DB00062) Chloride ion (DB14547) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Platinum (DB12257)